CD80 and neoplasm: There was no significant difference in the total number of tumor-infiltrated, cytotoxic CD178 and granzyme B-expressing, IFN-γ or IL-17-producing NK1.1+NK cells (Figures 3(a)–3(d)) and in the total number of IL-12-, TNF-α-, and IL-10-producing, CD80, CD86, and I-A-expressing F4/80+ tumor-associated macrophages (Figures 3(e)–3(j)) between 4T1+saline- and 4T1+d-MAPPS-treated mice.